Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2015 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the Life Sciences Israel(TM) 2015 3rd Annual International Partnering Conference

TEL-AVIV, Israel, Feb. 12, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage,...
February 10, 2015 09:07 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Prices Public Offering of Its American Depository Shares

TEL-AVIV, Israel, Feb. 10, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
February 09, 2015 16:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Proposed Public Offering of Its American Depository Shares

TEL-AVIV, Israel, Feb. 9, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
January 29, 2015 07:13 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Provides Update on Progress With RHB-104 Ongoing Phase III Program for Crohn's Disease Following FDA Meeting

RedHill and Quest Diagnostics concluded a pre-submission meeting with U.S. FDA regarding RedHill's companion diagnostic test for the detection of MAP bacterium, an extension of RedHill's ongoing...
January 28, 2015 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the 17th Annual BIO CEO & Investor Conference

TEL-AVIV, Israel, Jan. 28, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage,...
January 09, 2015 06:05 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at Biotech Showcase(TM) 2015 Conference in San Francisco

TEL-AVIV, Israel, Jan. 9, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage,...
January 05, 2015 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Business Outlook and Anticipated Key Milestones for 2015

Upcoming milestones include: Top-line data from ongoing first Phase III study with RHB-105 for H. pylori infection expected Q2/2015 Top-line data from ongoing Phase III study with...
December 31, 2014 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Acceptance for Review of BEKINDA(TM) European Marketing Application for Oncology Support

The UK MHRA has validated the European marketing application for the indications of chemotherapy and radiotherapy-induced nausea and vomiting; MHRA's feedback is expected during H2/2015...
December 18, 2014 06:05 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Acquires Technology from University of Minnesota as Part of Ongoing RHB-104 Phase III Crohn's Program

The acquired diagnostic technology is intended for the detection of Mycobacterium avium subspecies paratuberculosis (MAP) bacterium; Increasing evidence supports the hypothesis that Crohn's...
December 17, 2014 06:05 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA(TM)) for Gastroenteritis and Gastritis

The randomized, double-blind, placebo-controlled Phase III study with RHB-102 for acute gastroenteritis and gastritis (the GUARD study) is underway in the U.S., with a planned enrollment of 320...